Disease burden of chronic hepatitis C in Brazil

Ferreira, Paulo Roberto Abrão; Brandão‐Mello, Carlos Eduardo; Estes, Chris; Júnior, Fernando Lopes Gonçales; Coelho, Henrique Sérgio Moraes; Razavi, Homie; Cheinquer, Hugo; Wolff, Fernando Herz; Ferraz, M.L.G.; Mendes-Corrêa, Maria Cássia

doi:10.1016/j.bjid.2015.04.004

Cited by 18 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Brazil, chronic HCV infection and alcohol consumption are a major public health problem[33,34]; nevertheless, in some regions HBV is still an important cause of cirrhosis and HCC[35]. Llovet et al[36] have shown that in Europe and North America, HCV and alcohol are more frequently associated with HCC than HBV, differently than what occurs in Asia and Africa.…”

Section: Discussionmentioning

confidence: 99%

Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study

Silva¹,

Miozzo²,

Dossin³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo determine the incidence of hepatocellular carcinoma (HCC) and the impact of HCC surveillance on early diagnosis and survival of cirrhotic outpatients.METHODSIn this retrospective cohort study, cirrhotic outpatients undergoing HCC surveillance between March 2005 and March 2014 were analyzed. Exclusion criteria were HIV coinfection; previous organ transplantation; diagnosis of HCC at first consultation; missing data in the medical chart; and less than 1 year of follow-up. Surveillance was carried out every six months using ultrasound and serum alpha-fetoprotein determination. Ten-year cumulative incidence and survival were estimated through Kaplan-Meier analysis.RESULTSFour hundred and fifty-three patients were enrolled, of which 57.6% were male. Mean age was 55 years. Hepatitis C virus and heavy use of alcohol were the main etiologic agents of cirrhosis. HCC was diagnosed in 75 patients (16.6%), with an estimated cumulative incidence of 2.6% in the 1st year, 15.4% in the 5th year, and 28.8% in the 10th year. Median survival was estimated at 17.6 mo in HCC patients compared to 234 mo in non-HCC patients (P < 0.001). Early-stage HCC was more often detected in patients who underwent surveillance every 6 mo or less (P = 0.05). However, survival was not different between patients with early stage vs non-early stage tumors [HR = 0.54 (0.15-1.89), P = 0.33].CONCLUSIONHCC is a frequent complication in patients with cirrhosis and adherence to surveillance programs favors early diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study

Silva¹,

Miozzo²,

Dossin³

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…Most of the HCV-infected individuals in Latin America are in Brazil with more than 2.5 million cases, being among the 10 countries with more cases worldwide 17,19,20. The second largest epidemiologic burden due to HCV is found in Mexico with 1.6 million cases.…”

Section: Hcv In Latin America: Burden Of Infection and Accessibility mentioning

confidence: 99%

“…Likewise, it was estimated that the peak incidence occurred in the mid to late 90s and predicted a slow decline in the prevalence for the next decades as a result of prophylactic measures and the effectiveness of current antiviral agents 17,25. However, due to the fact that 75% of HCV infections evolve into chronicity, the consequences of the natural course of the disease are observed decades after the infection; resulting in future high costs of monitoring, hospitalization, or transplantation for health care systems 17,18,20…”

Section: Hcv In Latin America: Burden Of Infection and Accessibility mentioning

confidence: 99%

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Trinks

Caputo

Hulaniuk³

et al. 2017

PGPM

View full text Add to dashboard Cite

In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excellent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 1 infection and the significant association of Native American ancestry with risk predictive single-nucleotide polymorphisms (SNPs) in IFNL4 and ITPA genes highlight the need to implement new treatment regimens in these populations. However, the universal accessibility to DAAs is still not a reality in the region as their high cost is one of the major, although not the only, limiting factors for their broad implementation. Therefore, under these circumstances, could the assessment of host genetic markers be a useful tool to prioritize DAA treatment until global access to these new drugs can be achieved? This review will summarize the scientific evidences and the potential implications of HCV pharmacogenomics in this rapidly evolving era of anti-HCV drug development.

show abstract

“…Los indicadores de carga más reportados por profesionales e instituciones son la incidencia, prevalencia, mortalidad [35,59,[65][66][67][68][69], años vividos con discapacidad (ylds-avd) [2,35], años de vida perdidos por muerte prematura (ylls-avpp), años de vida ajustados por discapacidad (dalys-avisas) [35,70] y años de vida ajustados por calidad (qalys-avac) [63]; frente a estas mediciones empleadas por profesionales e instituciones se observa una tendencia mundial al aumento de la comorbilidad relacionada con la edad y un aumento de avd relacionados con el crecimiento demográfico y envejecimiento (Tabla 2). Con respecto a la percepción de carga de las instituciones o de quienes las representan, no aparece reporte en la literatura consultada de un significado de carga de la enfermedad crónica que se relacione con la experiencia del cuidado.…”

Section: Carga Como Esfuerzo Económico Adicionalunclassified

Carga de la enfermedad crónica para los sujetos implicados en el cuidado

Carreño

Sánchez–Herrera

Carrillo

et al. 2016

Rev. Fac. Nac. Salud Pública

View full text Add to dashboard Cite

Carga de la enfermedad crónica para los sujetos implicados en el cuidadoThe burden of chronic disease for the subjects involved in the care:Carga da enfermidade crônica para os sujeitos implicados no cuidado ResumenObjetivo: determinar el significado que se ha dado al concepto de carga de la enfermedad crónica no transmisible en pacientes, cuidadores familiares, profesionales del área de la salud e instituciones prestadoras de servicios de salud. Metodología: revisión realizada mediante las bases de datos LILACS, Sage, Willey online Library, Scopus, Bireme, Scielo, ScienceDirect, PubMed, Cuiden y Proquest. Resultados: Se encontraron 538 artículos relacionados de los cuales se seleccionaron 58 para el análisis, agrupados en tres categorías: esfuerzo físico, esfuerzo psicosocial y esfuerzo económico adicional. Conclusiones: el significado de carga de la enfermedad crónica es construida entre pacientes y cuidadores desde la vivencia y los impactos en su ámbito privado, es decir en lo personal y familiar. Los profesionales de salud y las instituciones reconocen la importancia de la vivencia de la enfermedad en el paciente y la familia; sin embargo, dan prioridad al impacto económico que la carga tiene sobre las mismas instituciones y los sistemas de salud.-----------Palabras clave: enfermedad crónica, cuidadores, costo de enfermedad, personal de salud (Decs) AbstractObjective: to determine the meaning given to the concept of burden of chronic non-communicable disease among patients, family caregivers, health care professionals and health service institutions. Methodology: a systematic review conducted

show abstract

Disease burden of chronic hepatitis C in Brazil

Cited by 18 publications

References 18 publications

Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study

Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Carga de la enfermedad crónica para los sujetos implicados en el cuidado

Contact Info

Product

Resources

About